

GLAXOSMITHKLINE PLC

Form 6-K

July 13, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 13 July 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7040	16
  - d) Aggregated information  
Aggregated volume Price n/a (single transaction)
  - e) Date of the transaction 2018-07-12
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted  
 Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 a) Description of the financial instrument ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 b) Nature of the transaction paid to shareholders on 12  
 July 2018, on shares held  
 through the Company's Share  
 Reward Plan.  
 c) Price(s) and volume(s) Price(s) Volume(s)  
 £15.7040 59  
 d) Aggregated information n/a (single transaction)  
 Aggregated volume Price  
 e) Date of the transaction 2018-07-12  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr S Dingemans  
 b) Position/status Chief Financial Officer  
 c) Initial notification/ amendment Initial notification  
 2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted  
 Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 a) Description of the financial instrument ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 b) Nature of the transaction paid to shareholders on 12  
 July 2018, on shares held  
 through the Company's Share  
 Reward Plan.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7040	21
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-07-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance

c) Initial notification/ amendment	Initial notification
------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7040	10

d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-07-12	

f) Place of the transaction	London Stock Exchange (XLON)	
-----------------------------	------------------------------	--

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr L Miels  
President, Global
- b) Position/status Pharmaceuticals
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.7040 1
- d) Aggregated information Aggregated volume Price  
n/a (single transaction)
- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.				
c)	Price(s) and volume(s)	<table border="0"> <tr> <td style="padding-right: 20px;">Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.7040</td> <td>68</td> </tr> </table>	Price(s)	Volume(s)	£15.7040	68
Price(s)	Volume(s)					
£15.7040	68					
d)	Aggregated information Aggregated volume Price	n/a (single transaction)				
e)	Date of the transaction	2018-07-12				
f)	Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
----	---	--

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.				
c)	Price(s) and volume(s)	<table border="0"> <tr> <td style="padding-right: 20px;">Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.7040</td> <td>68</td> </tr> </table>	Price(s)	Volume(s)	£15.7040	68
Price(s)	Volume(s)					
£15.7040	68					
d)	Aggregated information Aggregated volume Price	n/a (single transaction)				
e)	Date of the transaction	2018-07-12				
f)	Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7040	38
  - d) Aggregated information  
Aggregated volume Price n/a (single transaction)
  - e) Date of the transaction 2018-07-12
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mrs V A Whyte
  - b) Position/status Company Secretary
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc

- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£15.7040 49
- d) Aggregated information n/a (single transaction)  
Aggregated volume Price
- e) Date of the transaction 2018-07-12
- f) Place of the transaction London Stock Exchange (XLON)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 13, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc